Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue

Summary

Gepotidacin is a new antibiotic that may potentially be used to treat prostatic infections and pharyngeal gonorrhoea. To date, no data exists on gepotidacin pharmacokinetics in those tissues. The present study is being carried out to determine concentrations of gepotidacin in plasma, prostate and tonsillar tissue of patients undergoing radical prostatectomy (RPE) for localized prostate, simple prostatectomy (PE) for benign prostate hyperplasia (BPH) or tonsillectomy (TE). This will contribute to a more complete understanding of the drug's penetration to its site of action.

Timeline

Start

2021-01-29

Primary completion

2023-05-27

Completion

2023-05-27

Drugs

Indications